All News

This month's OTC Cases focus on influenza.

Mitchel Rothholz, RPh, MBA, chief of governance and state affiliates at the American Pharmacists Association (APhA) and executive director of the APhA Foundation, discusses the results of a nationwide survey of pharmacists during the ongoing pandemic.

Probiotic Pearls Women’s helps support digestive and immune health.

Linaclotide (Linzess) is indicated for irritable bowel syndrome with constipation and chronic idiopathic constipation.

Independent pharmacies are getting closer to ending DIR fees for good, thanks to the work of organizations, such as the NCPA.

Symptoms of gonorrhea include painful urination, pain or swelling in the affected area, vaginal bleeding, and abdominal pain.

Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses major trends in the atherosclerotic cardiovascular disease and LDL-C management treatment landscape this year.

Expert panel discusses the current state of the pharmacy technician role, how COVID-19 changed the perception of pharmacy technicians, and updates across the legislative and regulatory landscape for pharmacy technician–administered tests and vaccines.

Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses projections for inclisiran’s use in clinical and pharmacy settings.

Gaps in vaccination rates may be related to access and not just distrust and skepticism, investigators from Ohio State University find.

New study results show that of those who tested or were presumed positive for SARS-CoV-2, 44% developed neurological symptoms.

Investigators learned that the degree of response depended on whether an individual has had 1, 2, 3, or 4, exposures through infection, vaccination, or both.

The tislelizumab combination met the primary endpoint of OS in patients with programmed death ligand 1 (PD-L1) expression, with additional follow-up needed to assess OS benefits in the intention-to-treat population.

Pharmacy managers would do well to stay atop of literature and developments, but also learn to engage others within and outside of pharmacy in order to elicit their support and also acquire ideas.

Some study limitations include that follow-up data were missing for some patients who dropped out of the study during the follow-up stages and the timing of the follow-up echocardiograms were random and driven by preference versus standard protocol.

Ten quiz questions to assess your knowledge on common symptoms and treatments for glaucoma.

Kimmtrak found to be the first therapy to demonstrate a survival benefit for HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma.

A machine-learning method called XGBoost provided the highest overall accuracy, despite being the least complex model.

Even after some pharmacy school classes resumed in-person, students had myriad barriers and motivators to attending because of the COVID-19 pandemic.

Fungicure Medicated Anti-Fungal Wash helps eliminate common fungus that can attack healthy skin.

Efgartigimod alfa-fcab (Vyvgart) is a human immunoglobulin G1 antibody fragment indicated for the treatment of generalized myasthenia gravis.

Gliomas begin in the glial cells that surround nerve cells and help them function.

Pharmacists can offer guidance on proper use of therapies and encourage adherence to regimens.

These findings suggest people with indications for PrEP may confront an access barrier if they live in a state that restricts scope of practice, according to the study.

The kit helps detect SARS-CoV-2 RNA in nasopharyngeal, anterior nasal, mid-turbinate nasal or oropharyngeal swab specimens from individuals suspected of COVID-19 by their health care provider.

This month features asciminib (Scemblix), pilocarpine HCI ophthalmic solution (Vuity), and amphetamine (Dyanavel XR).

Data from 4 analyses show that individuals treated with the drug achieved non-inferior vision gains compared with aflibercept.

Both data sets confirm previously announced results showing that the boost protects against the variant.

Investigators say that the post-acute sequalae markers are Epstein-Barr virus (EBV) DNA levels in the blood, pre-existing types 2 diabetes, the presence of certain antibodies, and SARS-CoV-2 RNA levels in the blood.

The 2 drugs are the first small molecule JAK-1 inhibitors to be approved in the United States as treatment options for patients who are not responding to other therapies.